it is time for a change in progens boardroom , page-8

in a nutshell, not sure. if i had an idea of what the BOD can and cannot do - i would've sold two years ago and started buying again this year.....LOL.

in all honesty, i foresee three possible outcomes:

1. smaller scale regional deal for pi-88/liver.
2. larger scale deal for pi-88.
3. merger with a larger big pharma for the IP+cash.

ideally, i'd like to see something good to come from this science. that will take deep pockets and the know-how of an established big pharma. pi-88 needs to be trialled against many indication(s) and at many different stages of the cancer(s)....the earlier the better.

if you've got a good science but limited resources...it's a shame that this has turned into a game of poker or a game of chicken. this could've been handled so much better than what's happened....but their credibility can be redeemed in my eyes if they can actually pull something good off.

Mal & Co., if you're listening....we're counting on you.....and your redemption is at stake. Where's Justus' hat? It's time to pull the fcking ra88it out. LOL.